You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDroperidol
Accession NumberDB00450  (APRD00939)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)
Structure
Thumb
Synonyms
1-(1-(3-(P-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
1-(1-(4-(P-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
1-{1-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one
1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-2,3-dihydro-1H-benzo[D]imidazol-2-one
Droperidol
Dropéridol
Droperidolo
Droperidolum
External Identifiers
  • McN-JR 4749
  • R 4749
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Droperidol Injectionliquid2.5 mgintramuscular; intravenousNovopharm Limited1998-04-202002-03-14Canada
Droperidol Injection USP 2.5mg/mlsolution2.5 mgintramuscular; intravenousSandoz Canada Incorporated1995-12-31Not applicableCanada
Inapsineinjection2.5 mg/mLintramuscular; intravenousAkorn, Inc.1996-07-01Not applicableUs
Inapsineinjection2.5 mg/mLintramuscular; intravenousAkorn, Inc.1996-07-01Not applicableUs
Inapsine Inj 2.5mg/mlliquid2.5 mgintramuscular; intravenousJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1982-12-311998-08-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Droperidolinjection, solution2.5 mg/mLintramuscular; intravenousHospira, Inc.1988-02-29Not applicableUs
Droperidolinjection, solution2.5 mg/mLintramuscular; intravenousAmerican Regent, Inc.1990-09-30Not applicableUs
Droperidolinjection, solution2.5 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2012-10-18Not applicableUs
Droperidolinjection, solution2.5 mg/mLintramuscular; intravenousCardinal Health1990-09-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DehydrobenzperidolJanssen
DridolProstrakan
DroleptanDaiichi Sankyo
DropedolExcelsior
DropelSiu Guan
DroperdalCristália
DroperidolsGrindeks
XomolixArzneimittel ProStrakan
Brand mixtures
NameLabellerIngredients
Innovar InjJanssen Pharmaceutica, Division Of Janssen Ortho Inc.
SaltsNot Available
Categories
UNIIO9U0F09D5X
CAS number548-73-2
WeightAverage: 379.4274
Monoisotopic: 379.169605168
Chemical FormulaC22H22FN3O2
InChI KeyInChIKey=RMEDXOLNCUSCGS-UHFFFAOYSA-N
InChI
InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
IUPAC Name
1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • Butyrophenone
  • Benzimidazole
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Benzoyl
  • Tetrahydropyridine
  • N-substituted imidazole
  • Hydropyridine
  • Gamma-aminoketone
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationDroperidol is ssed to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
PharmacodynamicsDroperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias.
Mechanism of actionThe exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine(2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well.
Related Articles
AbsorptionCompletely absorbed following intramuscular administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Extensively metabolized.

Route of eliminationNot Available
Half lifeBiphasic distribution. The rapid distribution phase is 1.4 ± 0.5 minutes and the slower distribution phase is 14.3 ± 6.5 minutes. Elimination half-life in adults is 134 ± 13 minutes and may be increased in geriatric patients. In children, it is 101.5 ± 26.4 minutes.
ClearanceNot Available
ToxicityThe intravenous LD50 of droperidol is 20-43 mg/kg in mice; 30 mg/kg in rats; 25 mg/kg in dogs and 11-13 mg/kg in rabbits. The intramuscular LD50 of droperidol is 195 mg/kg in mice, 104-110 mg/kg in rats; 97 mg/kg in rabbits and 200 mg/kg in guinea pigs. The manifestations of droperidol overdosage are an extension of its pharmacologic actions.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9602
Caco-2 permeable-0.7521
P-glycoprotein substrateSubstrate0.7471
P-glycoprotein inhibitor IInhibitor0.9128
P-glycoprotein inhibitor IIInhibitor0.7451
Renal organic cation transporterInhibitor0.67
CYP450 2C9 substrateNon-substrate0.7884
CYP450 2D6 substrateNon-substrate0.8756
CYP450 3A4 substrateSubstrate0.6751
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9279
Ames testNon AMES toxic0.6353
CarcinogenicityNon-carcinogens0.9104
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5820 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8955
hERG inhibition (predictor II)Inhibitor0.835
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abraxis pharmaceutical products
  • Astrazeneca lp
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Smith and nephew solopak div smith and nephew
  • Solopak laboratories inc
  • Watson laboratories inc
  • Akorn inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintramuscular; intravenous2.5 mg/mL
Solutionintramuscular; intravenous2.5 mg
Injectionintramuscular; intravenous2.5 mg/mL
Liquidintramuscular; intravenous2.5 mg
Liquidintramuscular; intravenous
Prices
Unit descriptionCostUnit
Inapsine 2.5 mg/ml ampul4.59USD ml
Droperidol 2.5 mg/ml vial2.04USD ml
Droperidol 2.5 mg/ml ampul0.7USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point145-146.5Janssen, P.A.J. and Gardocki, J.F.; U.S. Patent 3,141,823; July 21, 1964; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium. Januen, P.A.J.; U.S. Patent 3,161,645; December 15,1964: assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.
water solubility4.21 mg/LNot Available
logP3.50SANGSTER (1993)
pKa7.46SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0966 mg/mLALOGPS
logP3.93ALOGPS
logP3.01ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)12.72ChemAxon
pKa (Strongest Basic)6.75ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.65 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity109.52 m3·mol-1ChemAxon
Polarizability40.31 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Janssen, P.A.J. and Gardocki, J.F.; U.S. Patent 3,141,823; July 21, 1964; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.
Januen, P.A.J.; U.S. Patent 3,161,645; December 15,1964: assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.

US3161645
General ReferencesNot Available
External Links
ATC CodesN05AD08
AHFS Codes
  • 28:24.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineDroperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineDroperidol may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Droperidol is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Droperidol is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Droperidol is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Droperidol is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Droperidol is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Droperidol is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Droperidol is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Droperidol.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Droperidol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Droperidol is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Droperidol.
AmantadineAmantadine may increase the QTc-prolonging activities of Droperidol.
AmiodaroneDroperidol may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Droperidol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Droperidol.
AmobarbitalThe risk or severity of adverse effects can be increased when Droperidol is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Droperidol is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Droperidol is combined with Amperozide.
AmphetamineDroperidol may decrease the stimulatory activities of Amphetamine.
AnagrelideDroperidol may increase the QTc-prolonging activities of Anagrelide.
ApomorphineApomorphine may increase the QTc-prolonging activities of Droperidol.
ArformoterolArformoterol may increase the QTc-prolonging activities of Droperidol.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Droperidol.
AripiprazoleThe risk or severity of adverse effects can be increased when Droperidol is combined with Aripiprazole.
Arsenic trioxideDroperidol may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherDroperidol may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Articaine.
AsenapineDroperidol may increase the QTc-prolonging activities of Asenapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Droperidol.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Droperidol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Droperidol.
AzaperoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Azaperone.
AzelastineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Droperidol.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Droperidol.
BaclofenThe risk or severity of adverse effects can be increased when Droperidol is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Droperidol is combined with Barbital.
BedaquilineDroperidol may increase the QTc-prolonging activities of Bedaquiline.
BenzocaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Benzocaine.
BenzphetamineDroperidol may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Droperidol is combined with Benzyl alcohol.
BortezomibBortezomib may increase the QTc-prolonging activities of Droperidol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Droperidol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
BrimonidineThe risk or severity of adverse effects can be increased when Droperidol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Droperidol.
BrompheniramineThe risk or severity of adverse effects can be increased when Droperidol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Droperidol is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Droperidol.
BuprenorphineThe risk or severity of adverse effects can be increased when Droperidol is combined with Buprenorphine.
BuserelinBuserelin may increase the QTc-prolonging activities of Droperidol.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Droperidol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Droperidol.
ButacaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Droperidol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Droperidol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Droperidol is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Droperidol is combined with Butorphanol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Droperidol.
CarbamazepineThe risk or severity of adverse effects can be increased when Droperidol is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Droperidol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Droperidol is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Droperidol is combined with Carisoprodol.
CeritinibDroperidol may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Droperidol is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Droperidol is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Droperidol is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Chloroprocaine.
ChloroquineDroperidol may increase the QTc-prolonging activities of Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Droperidol is combined with Chlorphenamine.
ChlorphentermineDroperidol may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Droperidol is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Droperidol is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Cinchocaine.
CiprofloxacinDroperidol may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideDroperidol may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Droperidol.
CitalopramDroperidol may increase the QTc-prolonging activities of Citalopram.
ClarithromycinDroperidol may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Droperidol is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Droperidol is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Droperidol is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Droperidol is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Droperidol is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Droperidol is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Droperidol is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Droperidol.
CocaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Droperidol.
CrizotinibDroperidol may increase the QTc-prolonging activities of Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Droperidol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Droperidol.
CyproheptadineThe risk or severity of adverse effects can be increased when Droperidol is combined with Cyproheptadine.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Droperidol.
DantroleneThe risk or severity of adverse effects can be increased when Droperidol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Droperidol.
DapoxetineThe risk or severity of adverse effects can be increased when Droperidol is combined with Dapoxetine.
DasatinibDasatinib may increase the QTc-prolonging activities of Droperidol.
DegarelixDegarelix may increase the QTc-prolonging activities of Droperidol.
deramciclaneThe risk or severity of adverse effects can be increased when Droperidol is combined with deramciclane.
DesfluraneDesflurane may increase the QTc-prolonging activities of Droperidol.
DesfluraneThe risk or severity of adverse effects can be increased when Droperidol is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Droperidol.
DesloratadineThe risk or severity of adverse effects can be increased when Droperidol is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Droperidol.
DetomidineThe risk or severity of adverse effects can be increased when Droperidol is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Droperidol is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Droperidol is combined with Dexmedetomidine.
DextroamphetamineDroperidol may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Droperidol.
DextromoramideThe risk or severity of adverse effects can be increased when Droperidol is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Droperidol is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Droperidol is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Droperidol is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Droperidol is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Droperidol.
DihydroetorphineThe risk or severity of adverse effects can be increased when Droperidol is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Droperidol is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Droperidol is combined with Dimenhydrinate.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Droperidol.
DiphenhydramineThe risk or severity of adverse effects can be increased when Droperidol is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Droperidol is combined with Diphenoxylate.
DisopyramideDroperidol may increase the QTc-prolonging activities of Disopyramide.
DofetilideDroperidol may increase the QTc-prolonging activities of Dofetilide.
DolasetronDroperidol may increase the QTc-prolonging activities of Dolasetron.
DomperidoneDroperidol may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Droperidol is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Droperidol.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
DoxylamineThe risk or severity of adverse effects can be increased when Droperidol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Droperidol is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
DronedaroneDroperidol may increase the QTc-prolonging activities of Dronedarone.
DrotebanolThe risk or severity of adverse effects can be increased when Droperidol is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Droperidol.
DyclonineThe risk or severity of adverse effects can be increased when Droperidol is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Droperidol is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Droperidol is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Droperidol is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Droperidol.
EliglustatDroperidol may increase the QTc-prolonging activities of Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Droperidol.
EntacaponeThe risk or severity of adverse effects can be increased when Droperidol is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Droperidol.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Droperidol.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Droperidol.
EribulinEribulin may increase the QTc-prolonging activities of Droperidol.
ErythromycinErythromycin may increase the QTc-prolonging activities of Droperidol.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Droperidol.
EscitalopramDroperidol may increase the QTc-prolonging activities of Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Droperidol is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Droperidol.
EthanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Droperidol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Droperidol.
EthosuximideThe risk or severity of adverse effects can be increased when Droperidol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Droperidol is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Droperidol is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Droperidol is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Droperidol is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Droperidol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Droperidol is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Droperidol.
EtoperidoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Droperidol is combined with Etorphine.
EzogabineEzogabine may increase the QTc-prolonging activities of Droperidol.
EzogabineThe risk or severity of adverse effects can be increased when Droperidol is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Droperidol.
FelbamateFelbamate may increase the QTc-prolonging activities of Droperidol.
FelbamateThe risk or severity of adverse effects can be increased when Droperidol is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Droperidol is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Droperidol is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Droperidol.
FexofenadineThe risk or severity of adverse effects can be increased when Droperidol is combined with Fexofenadine.
FingolimodFingolimod may increase the QTc-prolonging activities of Droperidol.
FlecainideDroperidol may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Droperidol is combined with Flibanserin.
FluconazoleFluconazole may increase the QTc-prolonging activities of Droperidol.
FludiazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Droperidol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Droperidol.
FluoxetineDroperidol may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolDroperidol may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Droperidol.
FluphenazineThe risk or severity of adverse effects can be increased when Droperidol is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Droperidol is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Droperidol is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Droperidol is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Droperidol.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Droperidol.
FosphenytoinThe risk or severity of adverse effects can be increased when Droperidol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Droperidol is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Droperidol.
GabapentinThe risk or severity of adverse effects can be increased when Droperidol is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Droperidol is combined with gabapentin enacarbil.
Gadobenic acidDroperidol may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Droperidol.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Droperidol is combined with Gamma Hydroxybutyric Acid.
GemifloxacinDroperidol may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Droperidol is combined with Glutethimide.
GoserelinGoserelin may increase the QTc-prolonging activities of Droperidol.
GranisetronDroperidol may increase the QTc-prolonging activities of Granisetron.
GuanfacineThe risk or severity of adverse effects can be increased when Droperidol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Droperidol is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Droperidol is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Droperidol is combined with Hexobarbital.
HistrelinHistrelin may increase the QTc-prolonging activities of Droperidol.
HydrocodoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Droperidol.
Hydroxyamphetamine hydrobromideDroperidol may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
HydroxyzineThe risk or severity of adverse effects can be increased when Droperidol is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Droperidol.
IbutilideDroperidol may increase the QTc-prolonging activities of Ibutilide.
IloperidoneDroperidol may increase the QTc-prolonging activities of Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Droperidol.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Droperidol.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Droperidol.
IndalpineThe risk or severity of adverse effects can be increased when Droperidol is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Droperidol.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Droperidol.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Droperidol.
IsofluraneThe risk or severity of adverse effects can be increased when Droperidol is combined with Isoflurane.
IsradipineIsradipine may increase the QTc-prolonging activities of Droperidol.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Droperidol.
IvabradineIvabradine may increase the QTc-prolonging activities of Droperidol.
KetamineThe risk or severity of adverse effects can be increased when Droperidol is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Droperidol is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Ketobemidone.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Droperidol.
LamotrigineThe risk or severity of adverse effects can be increased when Droperidol is combined with Lamotrigine.
LapatinibLapatinib may increase the QTc-prolonging activities of Droperidol.
LenvatinibDroperidol may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Droperidol.
LevetiracetamThe risk or severity of adverse effects can be increased when Droperidol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Droperidol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Droperidol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Droperidol is combined with Levodopa.
LevofloxacinDroperidol may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Droperidol is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Droperidol is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Droperidol is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Droperidol.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Droperidol.
LisdexamfetamineDroperidol may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Droperidol.
LithiumThe risk or severity of adverse effects can be increased when Droperidol is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Droperidol is combined with Lofentanil.
LopinavirDroperidol may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Droperidol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Droperidol.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Droperidol.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Droperidol.
Lu AA21004The risk or severity of adverse effects can be increased when Droperidol is combined with Lu AA21004.
LumefantrineDroperidol may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Droperidol is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Droperidol.
MeclizineThe risk or severity of adverse effects can be increased when Droperidol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Droperidol is combined with Medetomidine.
MefloquineMefloquine may increase the QTc-prolonging activities of Droperidol.
MelatoninThe risk or severity of adverse effects can be increased when Droperidol is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Melperone.
MephentermineDroperidol may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Droperidol.
MequitazineDroperidol may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Droperidol is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Droperidol is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Droperidol.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Droperidol is combined with Methadyl Acetate.
MethamphetamineDroperidol may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Droperidol is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Droperidol is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Droperidol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Droperidol is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Droperidol is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Droperidol is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenobarbital.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Droperidol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Droperidol.
MetyrosineDroperidol may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Droperidol.
MidazolamThe risk or severity of adverse effects can be increased when Droperidol is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Droperidol.
MilnacipranThe risk or severity of adverse effects can be increased when Droperidol is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
MirabegronMirabegron may increase the QTc-prolonging activities of Droperidol.
MirtazapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Droperidol.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Droperidol.
MoexiprilMoexipril may increase the QTc-prolonging activities of Droperidol.
MolindoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Droperidol.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Droperidol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
NabiloneThe risk or severity of adverse effects can be increased when Droperidol is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Droperidol is combined with Nalbuphine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Droperidol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Droperidol.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Droperidol.
NicardipineNicardipine may increase the QTc-prolonging activities of Droperidol.
NilotinibDroperidol may increase the QTc-prolonging activities of Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Droperidol is combined with Nitrous oxide.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Droperidol.
NormethadoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Droperidol.
OctreotideOctreotide may increase the QTc-prolonging activities of Droperidol.
OfloxacinDroperidol may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Droperidol is combined with Olanzapine.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Droperidol.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Droperidol.
OlopatadineThe risk or severity of adverse effects can be increased when Droperidol is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Droperidol is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Droperidol is combined with Opium.
OrphenadrineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Droperidol.
OsanetantThe risk or severity of adverse effects can be increased when Droperidol is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Droperidol is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Oxymorphone.
OxytocinOxytocin may increase the QTc-prolonging activities of Droperidol.
PaliperidoneDroperidol may increase the QTc-prolonging activities of Paliperidone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Droperidol.
PanobinostatDroperidol may increase the QTc-prolonging activities of Panobinostat.
ParaldehydeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Droperidol.
ParoxetineThe risk or severity of adverse effects can be increased when Droperidol is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Droperidol.
PazopanibDroperidol may increase the QTc-prolonging activities of Pazopanib.
PentamidineDroperidol may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Droperidol is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Droperidol.
PerampanelThe risk or severity of adverse effects can be increased when Droperidol is combined with Perampanel.
PerflutrenDroperidol may increase the QTc-prolonging activities of Perflutren.
PerospironeThe risk or severity of adverse effects can be increased when Droperidol is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Droperidol is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Droperidol.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Droperidol.
PhenobarbitalThe risk or severity of adverse effects can be increased when Droperidol is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Droperidol is combined with Phenoxyethanol.
PhentermineDroperidol may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Droperidol is combined with Phenytoin.
PimozideDroperidol may increase the QTc-prolonging activities of Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Droperidol.
PipamperoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Droperidol is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Droperidol is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Droperidol is combined with Pomalidomide.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Droperidol.
PramipexoleDroperidol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Droperidol.
PrilocaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Prilocaine.
PrimaquineDroperidol may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Primidone.
ProcainamideDroperidol may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Droperidol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Droperidol.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Droperidol.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Droperidol.
PropafenoneDroperidol may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Proparacaine.
PropofolPropofol may increase the QTc-prolonging activities of Droperidol.
PropofolThe risk or severity of adverse effects can be increased when Droperidol is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Droperidol.
PSD502The risk or severity of adverse effects can be increased when Droperidol is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Quazepam.
QuetiapineDroperidol may increase the QTc-prolonging activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Droperidol.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Droperidol.
QuinidineDroperidol may increase the QTc-prolonging activities of Quinidine.
QuinineDroperidol may increase the QTc-prolonging activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Droperidol is combined with Ramelteon.
RanolazineRanolazine may increase the QTc-prolonging activities of Droperidol.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Droperidol.
RemifentanilThe risk or severity of adverse effects can be increased when Droperidol is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Droperidol.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Droperidol.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Droperidol.
RisperidoneRisperidone may increase the QTc-prolonging activities of Droperidol.
RisperidoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Risperidone.
RitonavirRitonavir may increase the QTc-prolonging activities of Droperidol.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Droperidol.
RomifidineThe risk or severity of adverse effects can be increased when Droperidol is combined with Romifidine.
RopiniroleDroperidol may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Droperidol.
RotigotineDroperidol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Droperidol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Droperidol is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Droperidol.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Droperidol.
SaquinavirDroperidol may increase the QTc-prolonging activities of Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Droperidol is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Droperidol.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Droperidol.
SertindoleThe risk or severity of adverse effects can be increased when Droperidol is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Droperidol is combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Droperidol.
SevofluraneThe risk or severity of adverse effects can be increased when Droperidol is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Droperidol is combined with Sodium oxybate.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Droperidol.
SorafenibSorafenib may increase the QTc-prolonging activities of Droperidol.
SotalolDroperidol may increase the QTc-prolonging activities of Sotalol.
StiripentolThe risk or severity of adverse effects can be increased when Droperidol is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Droperidol is combined with Sufentanil.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Droperidol.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Droperidol.
SulpirideThe risk or severity of adverse effects can be increased when Droperidol is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Droperidol.
SunitinibSunitinib may increase the QTc-prolonging activities of Droperidol.
SuvorexantThe risk or severity of adverse effects can be increased when Droperidol is combined with Suvorexant.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Droperidol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Droperidol.
TasimelteonThe risk or severity of adverse effects can be increased when Droperidol is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Droperidol.
TelavancinDroperidol may increase the QTc-prolonging activities of Telavancin.
TelithromycinDroperidol may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Droperidol.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Droperidol.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Droperidol.
TetrabenazineDroperidol may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Droperidol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Droperidol is combined with Tetrodotoxin.
ThalidomideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Droperidol.
ThiamylalThe risk or severity of adverse effects can be increased when Droperidol is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Droperidol is combined with Thiopental.
ThioridazineDroperidol may increase the QTc-prolonging activities of Thioridazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Droperidol.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Droperidol.
ThiothixeneThe risk or severity of adverse effects can be increased when Droperidol is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Droperidol is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Droperidol is combined with Tiletamine.
TizanidineTizanidine may increase the QTc-prolonging activities of Droperidol.
TizanidineThe risk or severity of adverse effects can be increased when Droperidol is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Droperidol is combined with Tolcapone.
TolterodineTolterodine may increase the QTc-prolonging activities of Droperidol.
TopiramateThe risk or severity of adverse effects can be increased when Droperidol is combined with Topiramate.
ToremifeneDroperidol may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Droperidol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Droperidol is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Droperidol.
TrazodoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Droperidol.
TriazolamThe risk or severity of adverse effects can be increased when Droperidol is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Droperidol is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Droperidol is combined with Triflupromazine.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Droperidol.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Droperidol.
TriprolidineThe risk or severity of adverse effects can be increased when Droperidol is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Droperidol.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Droperidol.
VandetanibDroperidol may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Droperidol.
VemurafenibDroperidol may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Droperidol.
VigabatrinThe risk or severity of adverse effects can be increased when Droperidol is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Droperidol.
VilazodoneThe risk or severity of adverse effects can be increased when Droperidol is combined with Vilazodone.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Droperidol.
VorinostatVorinostat may increase the QTc-prolonging activities of Droperidol.
VortioxetineThe risk or severity of adverse effects can be increased when Droperidol is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Droperidol is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Droperidol is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Droperidol is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Droperidol is combined with Zimelidine.
ZiprasidoneDroperidol may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Droperidol.
ZolazepamThe risk or severity of adverse effects can be increased when Droperidol is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Droperidol.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Droperidol.
ZonisamideThe risk or severity of adverse effects can be increased when Droperidol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Droperidol is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Droperidol is combined with Zotepine.
ZuclopenthixolDroperidol may increase the QTc-prolonging activities of Zuclopenthixol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Droperidol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Grip G, Svensson BA, Gordh T Jr, Post C, Hartvig P: Histopathology and evaluation of potentiation of morphine-induced antinociception by intrathecal droperidol in the rat. Acta Anaesthesiol Scand. 1992 Feb;36(2):145-52. [PubMed:1549935 ]
  2. Hamik A, Peroutka SJ: Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol. 1989;24(5):307-10. [PubMed:2527092 ]
  3. Larson MD: The effect of antiemetics on pupillary reflex dilation during epidural/general anesthesia. Anesth Analg. 2003 Dec;97(6):1652-6. [PubMed:14633536 ]
  4. Gao HR, Shi TF, Yang CX, Zhang D, Zhang GW, Zhang Y, Jiao RS, Zhang H, Xu MY: The effect of dopamine on pain-related neurons in the parafascicular nucleus of rats. J Neural Transm (Vienna). 2010 May;117(5):585-91. doi: 10.1007/s00702-010-0398-3. Epub 2010 Apr 1. [PubMed:20358234 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Zupko I, Janossy K, Maul K, Marki A, Falkay G: Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102. [PubMed:12505540 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23